Global Antibody Drug Conjugates Contract Manufacturing Market Growth 2024, Forecast To 2033
12 Nov, 2024
The antibody drug conjugates contract manufacturing market has seen robust growth recently, projected to rise from $8.72 billion in 2023 to $9.57 billion in 2024 at a CAGR of 9.7%. Key factors behind this growth include the increasing prevalence of cancer, growing demand for targeted therapies, advancements in antibody drug conjugates, higher investments in research and development, regulatory approvals for new ADCs, and the expansion of pharmaceutical companies. The antibody drug conjugates contract manufacturing market is expected to grow to $14.00 billion by 2028, at a CAGR of 10.5%. The market growth is fueled by the rise of personalized medicine, expanding ADC applications beyond oncology, collaborations between biotech and pharma companies, and increased adoption of ADCs in clinical trials. Trends include advancements in biomarker identification, biotechnology, next-generation ADC technologies, linker and payload technologies, and AI integration in drug development.
Major Driver In The Antibody Drug Conjugates Contract Manufacturing Market
The expanding biopharmaceutical industry is projected to boost the growth of the antibody-drug conjugates (ADCs) contract manufacturing market, which focuses on creating drugs from biological sources and leverages advancements in biotechnology and the growing need for personalized medicine. The ADCs contract manufacturing sector supports biopharmaceutical companies by providing specialized production services that enable efficient scaling and high-quality standards. For instance, the Department of Health and Social Care reported in May 2024 that the core biopharmaceutical sector generated £46.7 billion ($59.32 billion) in revenue in 2021/22, representing 43% of the total life sciences industry. As a result, the growth of the biopharmaceutical sector is directly driving the ADCs contract manufacturing market, with expectations for further expansion in the coming years.
Request A Free Sample Of The Antibody Drug Conjugates Contract Manufacturing Market ReportAntibody Drug Conjugates Contract Manufacturing Market Competitive Landscape
AbbVie Inc., Eli Lilly and Company, Gilead Sciences Inc., Merck KGaA, Boehringer Ingelheim, Recipharm AB, Sigma-Aldrich, Sartorius AG, Curia, Lonza Group AG, Catalent Inc., KBI Biopharma, Alcami Corporation, Formosa Laboratories, BioVectra Inc., Axplora, Abzena PLC, ImmunoGen Inc., EirGenix Inc., Avid Bioservices Inc., Mersana Therapeutics, Cerbios-Pharma SA, Creative Biolabs, Aurigene Pharmaceutical Services Ltd., Sterling Pharma Solutions
Key Antibody Drug Conjugates Contract Manufacturing Market Trend
Companies in the antibody-drug conjugates contract manufacturing market are developing single-use reactors to improve production flexibility and reduce contamination. For example, in September 2024, MilliporeSigma launched the Mobius ADC Reactor, which enhances the manufacturing of antibody-drug conjugates by providing efficient, contamination-free production with improved scalability.
Purchase The Global Antibody Drug Conjugates Contract Manufacturing Market Report Directly And Get A Swift DeliveryGlobal Antibody Drug Conjugates Contract Manufacturing Market Segmentation
The antibody drug conjugates contract manufacturing market covered in this report is segmented –
1) By Type: Immunoglobulin G1(Igg1), Immunoglobulin G4(Igg4)
2) By Linker: Cleavable Linker, Non-Cleavable Linker
3) By Condition: Myeloma, Lymphoma, Breast Cancer, Other Conditions
4) By Phase: Clinical, Commercial
By Geography:The regions covered in the antibody drug conjugates contract manufacturing market report areAustralia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
North America was the largest region in the antibody drug conjugates contract manufacturing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period.
The Antibody Drug Conjugates Contract Manufacturing Global Market Report 2024 furnishes information about the global antibody drug conjugates contract manufacturing market, encompassing details like market size, projections for growth, segmentation across various sectors and regions, and an overview of competitors, including their revenues, profiles, and market shares. Furthermore, the report pinpoints potential opportunities and strategic directions derived from market trends and the strategies adopted by key competitors. The report also offers an assessment of how the COVID-19 pandemic, the Russia-Ukraine conflict, and increasing inflation have affected both global and regional markets, furnishing valuable strategic insights for businesses.